Ibrexafungerp Citrate

枸橼酸艾瑞芬净

Report date: 2025/11/20 15:28:42
QIDP

Base Information

Drug NameIbrexafungerp Citrate
Drug Alias NameIbrexafungerp citrateIbrexafungerp - SCYNEXISBrexafemmeIbrexafungerpBREXAFEMME +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action1,3-beta-glucan synthase inhibitors
Targets1,3-beta-glucan synthase
Therapy Area/IndicationsHistoplasmosisBlastomycosisCoccidioidomycosis +[13] 
Global Approved IndicationsCandidiasis, Vulvovaginal
Approved Indications in ChinaCandidiasis, Vulvovaginal
Original Approved Country/TerritoryUnited States
Original Approved Date2021/06/01
Country/TerritoryBelgiumBulgariaCanada +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesScynexis Inc
China Registration ClassN/A

Develop Information

Active CompaniesHansoh Pharmaceutical Group Company LtdGlaxosmithkline PlcScynexis Inc +[5] 
Inactive CompaniesSyngene International Ltd
Active IndicationsHistoplasmosisBlastomycosisCoccidioidomycosis +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeJ02AX
Related LinksN/A